By combining the fully biodegradable and biocompatible MediVas polymers with the Pfizer compounds, MediVas and Pfizer hope to create a product that can change the paradigm of how ophthalmic treatments are administered. Financial terms of the agreement were not disclosed.
MediVas believes that by combining therapeutic proteins and other biologics with a MediVas polymer, delivery routes that were previously unattainable, such as oral, intranasal, inhaled or subcutaneous injection can now be achieved.
“We are excited to enter this relationship with Pfizer and we are confident that by combining Pfizer's compounds with our best in class polymer delivery system we can help to increase patient compliance and significantly improve treatment of diseases of the eye,” commented Kenneth Carpenter, MediVas' president and CEO.